Neos Therapeutics, Inc. is a pharmaceutical company that is focused on developing, manufacturing and commercializing products utilizing its modified-release drug delivery technology platform. The Company's product candidates incorporate two prescribed medications for the treatment of attention deficit hyperactivity disorder (ADHD), methylphenidate and amphetamine. Its product candidates are extended-release (XR), medications in orally disintegrating tablets (ODT), as well as liquid suspension dosage forms. The Company's portfolio of products includes NT-0102, NT-0202, NT-0201 and Generic Tussionex. NT-0102 is an amphetamine XR-ODT used for the treatment of ADHD. NT-0201 is an amphetamine XR Liquid Suspension used for the treatment of ADHD. The Company manufactures and markets a generic equivalent to the branded product, Tussionex.